Management of Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Antiretroviral (ARV) Combination Therapy Including Raltegravir (MK-0518-138)

• Status: Completed
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the management of HIV-1 participants treated with antiretroviral combination therapy including the integrase inhibitor raltegravir, all across the country of France.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: HIV Integrase Inhibitors; Integrase Inhibitors; Raltegravir Potassium

Criteria

Inclusion Criteria:

• Participant Infected With HIV-1.

• Participant for whom raltegravir therapy has been decided and started less than 30 days prior to inclusion in the study.

• Participant who has received oral and written information about the study and who has agreed to the computer processing of his/her personal data.

Exclusion Criteria:

• Participant taking part in a clinical trial to assess raltegravir.

• Participant in whom raltegravir treatment was started more than 30 days ago.